Eudaimonia Partners’s Serina Therapeutics SER Stock Holding History

Eudaimonia Partners’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	1410
2021 Q1	$0	Buy	+1	New	+$70	﹤0.01%	1667

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Eudaimonia Partners's SER Position: Q2 2021 in Review

Eudaimonia Partners sold out of Serina Therapeutics (SER) in Q2 2021, closing a stake of 1 share.

Eudaimonia Partners first reported a position in SER in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 33 funds tracked by Wall St. Rank hold SER as of Q2 2021.

Eudaimonia Partners reported no remaining Serina Therapeutics position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 1 Serina Therapeutics share in Q2 2021.
Eudaimonia Partners first reported a position in Serina Therapeutics in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Serina Therapeutics position peaked at $0 in Q1 2021.
33 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.